These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30518828)

  • 1. Cryopreservation of primary B cells minimally influences their signaling responses.
    Hermansen JU; Tjønnfjord GE; Munthe LA; Taskén K; Skånland SS
    Sci Rep; 2018 Dec; 8(1):17651. PubMed ID: 30518828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
    Blix ES; Irish JM; Husebekk A; Delabie J; Forfang L; Tierens AM; Myklebust JH; Kolstad A
    BMC Cancer; 2012 Oct; 12():478. PubMed ID: 23072591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
    Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
    Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
    Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
    Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
    Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response.
    Huse K; Wogsland CE; Polikowsky HG; Diggins KE; Smeland EB; Myklebust JH; Irish JM
    Cytometry A; 2019 Apr; 95(4):442-449. PubMed ID: 30838773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
    Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
    Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.
    Frank DA; Mahajan S; Ritz J
    J Clin Invest; 1997 Dec; 100(12):3140-8. PubMed ID: 9399961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.
    Sainz-Perez A; Gary-Gouy H; Gaudin F; Maarof G; Marfaing-Koka A; de Revel T; Dalloul A
    J Immunol; 2008 Nov; 181(9):6051-60. PubMed ID: 18941194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
    Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
    Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
    J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
    Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
    J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant determination of phenotypic markers in chronic lymphocytic leukemia (CLL) lymphocytes after cryopreservation.
    Thurgood LA; Lower KM; Macardle C; Kuss BJ
    Exp Hematol; 2018 Jul; 63():28-32.e1. PubMed ID: 29705268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.